JP2006500393A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006500393A5 JP2006500393A5 JP2004534697A JP2004534697A JP2006500393A5 JP 2006500393 A5 JP2006500393 A5 JP 2006500393A5 JP 2004534697 A JP2004534697 A JP 2004534697A JP 2004534697 A JP2004534697 A JP 2004534697A JP 2006500393 A5 JP2006500393 A5 JP 2006500393A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- hydroxy
- methyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 hydroxy, carboxy Chemical group 0.000 claims 352
- 125000000217 alkyl group Chemical group 0.000 claims 239
- 125000001072 heteroaryl group Chemical group 0.000 claims 55
- 125000003545 alkoxy group Chemical group 0.000 claims 51
- 125000003118 aryl group Chemical group 0.000 claims 51
- 125000001424 substituent group Chemical group 0.000 claims 45
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 38
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 32
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 32
- 125000004093 cyano group Chemical group *C#N 0.000 claims 31
- 229910052736 halogen Inorganic materials 0.000 claims 30
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 28
- 150000002367 halogens Chemical class 0.000 claims 28
- 229910052739 hydrogen Inorganic materials 0.000 claims 28
- 239000001257 hydrogen Substances 0.000 claims 28
- 125000000753 cycloalkyl group Chemical group 0.000 claims 27
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 24
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 22
- 125000004452 carbocyclyl group Chemical group 0.000 claims 21
- 150000002431 hydrogen Chemical class 0.000 claims 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 20
- 229910052757 nitrogen Inorganic materials 0.000 claims 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 17
- 125000003342 alkenyl group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 15
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 125000001153 fluoro group Chemical group F* 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 8
- 208000002193 Pain Diseases 0.000 claims 8
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 8
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 8
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 8
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 7
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 5
- 125000006509 3,4-difluorobenzyl group Chemical group [H]C1=C(F)C(F)=C([H])C(=C1[H])C([H])([H])* 0.000 claims 5
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 229910052731 fluorine Inorganic materials 0.000 claims 5
- 239000011737 fluorine Chemical group 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 5
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 4
- 208000000094 Chronic Pain Diseases 0.000 claims 4
- 206010011224 Cough Diseases 0.000 claims 4
- 208000011231 Crohn disease Diseases 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 4
- 208000030814 Eating disease Diseases 0.000 claims 4
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 4
- 206010026749 Mania Diseases 0.000 claims 4
- 208000019695 Migraine disease Diseases 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 4
- 208000028017 Psychotic disease Diseases 0.000 claims 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 4
- 206010046543 Urinary incontinence Diseases 0.000 claims 4
- 208000005298 acute pain Diseases 0.000 claims 4
- 230000001919 adrenal effect Effects 0.000 claims 4
- 230000036506 anxiety Effects 0.000 claims 4
- 206010003119 arrhythmia Diseases 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 208000028683 bipolar I disease Diseases 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 235000014632 disordered eating Nutrition 0.000 claims 4
- 230000004064 dysfunction Effects 0.000 claims 4
- 206010015037 epilepsy Diseases 0.000 claims 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 4
- 206010027599 migraine Diseases 0.000 claims 4
- 230000036651 mood Effects 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 208000021722 neuropathic pain Diseases 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 201000000980 schizophrenia Diseases 0.000 claims 4
- 208000011117 substance-related disease Diseases 0.000 claims 4
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 3
- 125000006507 2,4-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(F)C(=C1[H])C([H])([H])* 0.000 claims 3
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 claims 3
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 3
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 3
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 3
- 125000006494 2-trifluoromethyl benzyl group Chemical group [H]C1=C([H])C([H])=C(C(=C1[H])C([H])([H])*)C(F)(F)F 0.000 claims 3
- 125000005806 3,4,5-trimethoxybenzyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1C([H])([H])* 0.000 claims 3
- 125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 claims 3
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 3
- 125000006279 3-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Br)=C1[H])C([H])([H])* 0.000 claims 3
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims 3
- 125000006482 3-iodobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(I)=C1[H])C([H])([H])* 0.000 claims 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 3
- 125000006495 3-trifluoromethyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])*)C(F)(F)F 0.000 claims 3
- 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 claims 3
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 3
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical group [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 claims 3
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 3
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 3
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 claims 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 3
- 125000000173 4-trifluoromethoxy benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC(F)(F)F)C([H])([H])* 0.000 claims 3
- 125000001318 4-trifluoromethylbenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(F)(F)F 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 3
- 230000007370 cognitive improvement Effects 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 230000006993 memory improvement Effects 0.000 claims 3
- 125000005322 morpholin-1-yl group Chemical group 0.000 claims 3
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 claims 3
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 3
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 230000006641 stabilisation Effects 0.000 claims 3
- 238000011105 stabilization Methods 0.000 claims 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 2
- 125000006280 2-bromobenzyl group Chemical group [H]C1=C([H])C(Br)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims 2
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000006180 3-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 206010013654 Drug abuse Diseases 0.000 claims 2
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 claims 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 2
- 108010020615 nociceptin receptor Proteins 0.000 claims 2
- 201000009032 substance abuse Diseases 0.000 claims 2
- 231100000736 substance abuse Toxicity 0.000 claims 2
- 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- OYGRPMXMTBVAQE-MUUNZHRXSA-N 1-(4-fluorophenyl)-3-[(2r)-2-hydroxy-3-(3-hydroxypropylamino)propyl]-8-[(8-methylnaphthalen-1-yl)methyl]-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C=12C(C)=CC=CC2=CC=CC=1CN(CC1)CCC1(C(N(C[C@H](O)CNCCCO)C1)=O)N1C1=CC=C(F)C=C1 OYGRPMXMTBVAQE-MUUNZHRXSA-N 0.000 claims 1
- IMGQPABKFUXCTN-GDLZYMKVSA-N 1-(4-fluorophenyl)-3-[(2r)-2-hydroxy-3-[3-(methylamino)propylamino]propyl]-8-[(8-methylnaphthalen-1-yl)methyl]-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1CN(CC=2C3=C(C)C=CC=C3C=CC=2)CCC21C(=O)N(C[C@H](O)CNCCCNC)CN2C1=CC=C(F)C=C1 IMGQPABKFUXCTN-GDLZYMKVSA-N 0.000 claims 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 1
- 125000001847 2-phenylcyclopropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1([H])C([H])([H])C1([H])* 0.000 claims 1
- AWYSBTQCCOWYQC-HHHXNRCGSA-N 3-[(2r)-3-(dimethylamino)-2-hydroxypropyl]-1-(4-fluorophenyl)-8-[(8-methylnaphthalen-1-yl)methyl]-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1CN(CC=2C3=C(C)C=CC=C3C=CC=2)CCC21C(=O)N(C[C@H](O)CN(C)C)CN2C1=CC=C(F)C=C1 AWYSBTQCCOWYQC-HHHXNRCGSA-N 0.000 claims 1
- HWQFSZPVJZOLNP-SSEXGKCCSA-N 3-[(2r)-3-[3-(dimethylamino)propylamino]-2-hydroxypropyl]-1-(4-fluorophenyl)-8-[(8-methylnaphthalen-1-yl)methyl]-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1CN(CC=2C3=C(C)C=CC=C3C=CC=2)CCC21C(=O)N(C[C@H](O)CNCCCN(C)C)CN2C1=CC=C(F)C=C1 HWQFSZPVJZOLNP-SSEXGKCCSA-N 0.000 claims 1
- ALXBWOVLKSYZNY-RUZDIDTESA-N 3-[(2r)-3-amino-2-hydroxypropyl]-1-(4-fluorophenyl)-8-[(8-methylnaphthalen-1-yl)methyl]-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C=12C(C)=CC=CC2=CC=CC=1CN(CC1)CCC1(C(N(C[C@H](O)CN)C1)=O)N1C1=CC=C(F)C=C1 ALXBWOVLKSYZNY-RUZDIDTESA-N 0.000 claims 1
- NNFWJRYNXMYWJE-JOCHJYFZSA-N 3-[(2r)-3-amino-2-hydroxypropyl]-8-cyclooctyl-1-(4-fluorophenyl)-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1CN(C2CCCCCCC2)CCC21C(=O)N(C[C@H](O)CN)CN2C1=CC=C(F)C=C1 NNFWJRYNXMYWJE-JOCHJYFZSA-N 0.000 claims 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 125000005141 aryl amino sulfonyl group Chemical group 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000000068 chlorophenyl group Chemical group 0.000 claims 1
- 230000003930 cognitive ability Effects 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims 1
- 210000002816 gill Anatomy 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical compound OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 0 *C1C2C1CCC2 Chemical compound *C1C2C1CCC2 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40913402P | 2002-09-09 | 2002-09-09 | |
| US60/409,134 | 2002-09-09 | ||
| PCT/US2003/027956 WO2004022558A2 (en) | 2002-09-09 | 2003-09-05 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006500393A JP2006500393A (ja) | 2006-01-05 |
| JP2006500393A5 true JP2006500393A5 (https=) | 2006-10-26 |
| JP4712384B2 JP4712384B2 (ja) | 2011-06-29 |
Family
ID=31978719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004534697A Expired - Fee Related JP4712384B2 (ja) | 2002-09-09 | 2003-09-05 | Ｏｒｌ−１受容体介在障害の治療に有用なヒドロキシアルキル置換１，３，８−トリアザスピロ［４．５］デカン−４−オン誘導体 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US7081463B2 (https=) |
| EP (1) | EP1601674B1 (https=) |
| JP (1) | JP4712384B2 (https=) |
| KR (1) | KR20050043935A (https=) |
| CN (1) | CN100402529C (https=) |
| AR (1) | AR041205A1 (https=) |
| AU (1) | AU2003268512A1 (https=) |
| BR (1) | BR0306309A (https=) |
| CA (1) | CA2498275C (https=) |
| CL (1) | CL2003001814A1 (https=) |
| EA (1) | EA009369B1 (https=) |
| MX (1) | MXPA05002622A (https=) |
| NO (1) | NO20051743L (https=) |
| NZ (1) | NZ538307A (https=) |
| PL (1) | PL377047A1 (https=) |
| RS (1) | RS20050208A (https=) |
| TW (1) | TWI296627B (https=) |
| WO (1) | WO2004022558A2 (https=) |
| ZA (1) | ZA200502836B (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ538307A (en) | 2002-09-09 | 2008-04-30 | Janssen Pharmaceutica Nv | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
| US20080287478A1 (en) * | 2003-05-23 | 2008-11-20 | Lars Bo Laurenborg Hansen | Nociceptin Analogues and Uses Thereof |
| AR046756A1 (es) | 2003-12-12 | 2005-12-21 | Solvay Pharm Gmbh | Derivados de hidronopol como agonistas de receptores orl-1 humanos. |
| US20060178390A1 (en) * | 2004-08-02 | 2006-08-10 | Alfonzo Jordan | 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
| CN101273046B (zh) | 2005-09-28 | 2011-05-25 | 弗·哈夫曼-拉罗切有限公司 | 作为加压素受体拮抗剂的吲哚-3-基-羰基氮杂螺环衍生物 |
| TW200819457A (en) * | 2006-08-30 | 2008-05-01 | Actelion Pharmaceuticals Ltd | Spiro antibiotic derivatives |
| KR20090087042A (ko) * | 2006-11-28 | 2009-08-14 | 얀센 파마슈티카 엔.브이. | 알콜 남용, 중독 및 의존증 치료방법 |
| CN103202840B (zh) | 2006-11-28 | 2015-02-11 | 詹森药业有限公司 | 3-(3-氨基-2-(r)-羟基-丙基)-1-(4-氟-苯基)-8-(8-甲基-萘-1-基甲基)-1,3,8-三氮杂-螺[4.5]癸烷-4-酮的盐 |
| JP5490677B2 (ja) * | 2007-04-09 | 2014-05-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 不安及び鬱病の処置のためのｏｒｌ−１受容体リガンドとしての１，３，８−三置換−１，３，８−トリアザ−スピロ［４．５］デカン−４−オン誘導体 |
| US20100076003A1 (en) * | 2008-09-19 | 2010-03-25 | Kathleen Battista | 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators |
| UA107943C2 (xx) * | 2009-11-16 | 2015-03-10 | Lilly Co Eli | Сполуки спіропіперидину як антагоністи рецептора orl-1 |
| US9611257B2 (en) | 2012-12-21 | 2017-04-04 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| EP3406607A1 (en) | 2012-12-21 | 2018-11-28 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| UA118548C2 (uk) | 2012-12-21 | 2019-02-11 | Епізайм, Інк. | Тетрагідро- та дигідроізохіноліни як інгібітори prmt5 та їх застосування |
| CA2894157A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| JP2016505000A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| TW201607923A (zh) | 2014-07-15 | 2016-03-01 | 歌林達有限公司 | 被取代之氮螺環（４．５）癸烷衍生物 |
| EP3177288A4 (en) | 2014-08-04 | 2018-04-04 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| KR102043337B1 (ko) | 2014-08-28 | 2019-11-11 | 아셰뉴론 에스아 | 글리코시다제 저해제 |
| JP7011596B2 (ja) * | 2015-12-02 | 2022-02-10 | アストライア セラピューティクス， エルエルシー | ピペリジニルノシセプチン受容体化合物 |
| US10112924B2 (en) | 2015-12-02 | 2018-10-30 | Astraea Therapeutics, Inc. | Piperdinyl nociceptin receptor compounds |
| CA3014572C (en) | 2016-02-25 | 2023-10-03 | Asceneuron S.A. | Acid addition salts of piperazine derivatives |
| KR20180132629A (ko) | 2016-02-25 | 2018-12-12 | 아셰뉴론 에스아 | 글리코시다제 저해제 |
| AU2017222964B2 (en) | 2016-02-25 | 2020-01-02 | Asceneuron S. A. | Glycosidase inhibitors |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| US11213525B2 (en) | 2017-08-24 | 2022-01-04 | Asceneuron Sa | Linear glycosidase inhibitors |
| MX2020003242A (es) | 2017-09-22 | 2020-09-18 | Jubilant Epipad LLC | Compuestos heterociclicos como inhibidores de pad. |
| AU2018352142B2 (en) | 2017-10-18 | 2022-08-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
| KR20200085836A (ko) | 2017-11-06 | 2020-07-15 | 주빌런트 프로델 엘엘씨 | Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체 |
| BR112020010322A2 (pt) | 2017-11-24 | 2020-11-17 | Jubilant Episcribe Llc | composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer |
| SG11202008950PA (en) | 2018-03-13 | 2020-10-29 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
| WO2020039029A1 (en) * | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Spiro compounds as glycosidase inhibitors |
| WO2020039027A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Pyrrolidine glycosidase inhibitors |
| JP7407171B2 (ja) | 2018-08-22 | 2023-12-28 | エースニューロン・ソシエテ・アノニム | グリコシダーゼ阻害剤として有用なピペラジン誘導体のコハク酸付加塩及びフマル酸付加塩 |
| WO2020039028A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US677421A (en) * | 1900-10-19 | 1901-07-02 | Kate Hatch Mcrae | Cake-beater. |
| US3155699A (en) * | 1960-03-30 | 1964-11-03 | Mobay Chemical Corp | Purification of isocyanates by reduction of the hydrolyzable chlorine and acid content |
| US3155670A (en) * | 1962-06-22 | 1964-11-03 | Res Lab Dr C Janssen N V | 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes |
| US3161644A (en) * | 1962-06-22 | 1964-12-15 | Res Lab Dr C Janssen N V | 1-benzyl-4-substituted piperidines |
| US3238216A (en) | 1963-06-20 | 1966-03-01 | Res Lab Dr C Janssen N V | Substituted 1, 3, 8-triaza-spiro (4, 5) decanes |
| US3839340A (en) * | 1968-09-27 | 1974-10-01 | Fmc Corp | Substituted 1,3,8-triazaspiro{8 4.5{9 decanes |
| US3629267A (en) * | 1968-10-28 | 1971-12-21 | Smith Kline French Lab | Benzoheterocyclicalkyl derivatives of 4-(2-keto -1-benzimidazolinyl)-piperidine 4-(2-keto - 1 - benzimidazolinyl) -1 2 3 6 tetrahydropyridine 1 - phenyl - 1 3 8-triazaspiro(4 5)decan - 4 - one and 2 4 9-triazaspiro(5 5)undecan-1 3 5-trione |
| US3859340A (en) * | 1970-09-09 | 1975-01-07 | Squibb & Sons Inc | ' -methylfluorene-2-acetic acid |
| US4020072A (en) * | 1976-05-04 | 1977-04-26 | E. R. Squibb & Sons, Inc. | 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines |
| JPS54109983A (en) * | 1978-02-13 | 1979-08-29 | Sumitomo Chem Co Ltd | Novel spiroamine derivative and its preparation |
| US4329363A (en) * | 1978-09-08 | 1982-05-11 | Merck & Co., Inc. | Substituted mercapto acid amides and their use |
| US4526896A (en) * | 1978-12-26 | 1985-07-02 | Riker Laboratories, Inc. | Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof |
| US4329353A (en) * | 1980-10-22 | 1982-05-11 | Janssen Pharmaceutica, N.V. | 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof |
| JPS57212180A (en) * | 1981-06-19 | 1982-12-27 | Yoshitomi Pharmaceut Ind Ltd | Tetrahydrofuran(thiophene) compound |
| WO1988000190A1 (en) | 1986-06-25 | 1988-01-14 | Massachusetts Institute Of Technology | Optically active derivatives of glycidol |
| IL96507A0 (en) | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
| US5486362A (en) * | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
| DE4135473A1 (de) | 1991-10-28 | 1993-04-29 | Bayer Ag | Triazaspirodecanon-methylchromane |
| EP0661972A1 (en) | 1991-12-27 | 1995-07-12 | Beth Israel Hospital | Use of spiperone or spiperone derivatives as immunosuppressant agents |
| FR2708606B1 (fr) * | 1993-07-30 | 1995-10-27 | Sanofi Sa | Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
| ATE191486T1 (de) | 1993-09-09 | 2000-04-15 | Scios Inc | Pseudo-oder nicht peptidartige bradykinin rezeptor antagoniste |
| US5739336A (en) | 1995-06-23 | 1998-04-14 | Syntex (U.S.A.) Inc. | 1,3,8-triaza- and 3,8-diaza-1-oxaspiro 4,5! decane derivatives |
| US5821219A (en) | 1995-08-11 | 1998-10-13 | Oregon Health Sciences University | Opioid antagonists and methods of their use |
| PT891332E (pt) | 1996-03-29 | 2004-07-30 | Pfizer | Derivados de 6-fenilpiridil-2-amina |
| CA2226058C (en) | 1997-01-30 | 2008-01-29 | F. Hoffmann-La Roche Ag | 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives |
| US6013652A (en) * | 1997-12-04 | 2000-01-11 | Merck & Co., Inc. | Spiro-substituted azacycles as neurokinin antagonists |
| ES2170446T3 (es) * | 1997-12-05 | 2002-08-01 | Hoffmann La Roche | Derivados de 1,3,8-triaza-espiro(4,5)decan-4-ona. |
| EP0921125B1 (en) | 1997-12-05 | 2002-01-30 | F. Hoffmann-La Roche Ag | 1,3,8-Triazaspiro[4,5]decan-4-on derivatives |
| US6277991B1 (en) * | 1998-05-18 | 2001-08-21 | Novo Nordisk A/S | 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes |
| WO1999059997A1 (en) * | 1998-05-18 | 1999-11-25 | Novo Nordisk A/S | Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes |
| DE69900220T2 (de) | 1998-06-12 | 2002-05-08 | F. Hoffmann-La Roche Ag, Basel | Diaza-spiro[3,5]nonan-Derivate |
| EP1087770A4 (en) * | 1998-06-15 | 2001-11-14 | Merck & Co Inc | PRENYL PROTEIN TRANSFERASE INHIBITORS |
| US6262066B1 (en) * | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
| ID29137A (id) | 1998-07-27 | 2001-08-02 | Schering Corp | Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1 |
| US6326379B1 (en) | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
| ATE289307T1 (de) * | 1998-10-23 | 2005-03-15 | Pfizer | 1,3,8-triazaspiro(4,5) decanon verbindungen als orl1-receptor agonisten |
| AU768708B2 (en) | 1998-11-20 | 2004-01-08 | Smithkline Beecham Laboratoires Pharmaceutiques | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists |
| JP2000169476A (ja) | 1998-12-09 | 2000-06-20 | Banyu Pharmaceut Co Ltd | ４−オキソイミダゾリジン−５−スピロ−含窒素複素環式化合物 |
| WO2001036418A1 (en) * | 1999-11-17 | 2001-05-25 | Novo Nordisk A/S | Novel triazaspirodecanones with high affinity for opioid receptor subtypes |
| DE19956598A1 (de) | 1999-11-25 | 2001-06-13 | Bosch Gmbh Robert | Ventil zum Steuern von Flüssigkeiten |
| US6686370B2 (en) | 1999-12-06 | 2004-02-03 | Euro-Celtique S.A. | Triazospiro compounds having nociceptin receptor affinity |
| JP2005231995A (ja) * | 1999-12-22 | 2005-09-02 | Meiji Seika Kaisha Ltd | オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物 |
| GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
| US6482829B2 (en) | 2000-06-08 | 2002-11-19 | Hoffmann-La Roche Inc. | Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor |
| AU2001262729A1 (en) | 2000-06-14 | 2001-12-24 | Banyu Pharmaceutical Co., Ltd | 4-oxoimidazolidine-2-spiro-nitrogenous heterocycle compounds |
| CA2443868C (en) | 2001-04-10 | 2011-01-25 | Ortho-Mcneil Pharmaceutical, Inc. | 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders |
| KR100628292B1 (ko) | 2001-04-18 | 2006-09-27 | 유로-셀티크 소시에떼 아노뉨 | 스파이로파이라졸 화합물 |
| US20030078278A1 (en) * | 2001-06-26 | 2003-04-24 | Pfizer Inc. | Spiropiperidine compounds as ligands for ORL-1 receptor |
| WO2003010168A1 (fr) | 2001-07-23 | 2003-02-06 | Banyu Pharmaceutical Co., Ltd. | Derive de 4-oxoimidazolidine-2-spiropiperidine |
| US20040014955A1 (en) * | 2001-12-17 | 2004-01-22 | Carlos Zamudio | Identification of essential genes of cryptococcus neoformans and methods of use |
| WO2003064425A1 (en) * | 2002-01-28 | 2003-08-07 | Pfizer Japan Inc. | N-substituted spiropiperidine compounds as ligands for orl-1 receptor |
| JP2005517007A (ja) | 2002-02-07 | 2005-06-09 | アクシス・ファーマスーティカルズ | ヒストンデアセチラーゼ阻害剤としての新規二環式ヒドロキサメート |
| NZ538307A (en) * | 2002-09-09 | 2008-04-30 | Janssen Pharmaceutica Nv | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
| WO2005016913A1 (en) | 2003-08-19 | 2005-02-24 | Pfizer Japan, Inc. | Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders |
| US20070254903A1 (en) | 2003-12-23 | 2007-11-01 | Arena Pharmaceuticals, Inc. | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof |
| TW200621244A (en) * | 2004-08-19 | 2006-07-01 | Vertex Pharma | Modulators of muscarinic receptors |
| AU2005287057A1 (en) | 2004-09-17 | 2006-03-30 | Osi Pharmaceuticals, Inc. | (spirocyclylamido) aminothiophene compounds as c-Kit proto- oncogene inhibitors |
| US7655670B2 (en) * | 2005-06-02 | 2010-02-02 | Janssen Pharmaceutica N.V. | 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators |
| KR20090087042A (ko) | 2006-11-28 | 2009-08-14 | 얀센 파마슈티카 엔.브이. | 알콜 남용, 중독 및 의존증 치료방법 |
| JP5490677B2 (ja) | 2007-04-09 | 2014-05-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 不安及び鬱病の処置のためのｏｒｌ−１受容体リガンドとしての１，３，８−三置換−１，３，８−トリアザ−スピロ［４．５］デカン−４−オン誘導体 |
| US20100076003A1 (en) | 2008-09-19 | 2010-03-25 | Kathleen Battista | 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators |
-
2003
- 2003-09-05 NZ NZ538307A patent/NZ538307A/en unknown
- 2003-09-05 AU AU2003268512A patent/AU2003268512A1/en not_active Abandoned
- 2003-09-05 KR KR1020057003938A patent/KR20050043935A/ko not_active Ceased
- 2003-09-05 PL PL377047A patent/PL377047A1/pl not_active Application Discontinuation
- 2003-09-05 CN CNB038249901A patent/CN100402529C/zh not_active Expired - Fee Related
- 2003-09-05 CA CA2498275A patent/CA2498275C/en not_active Expired - Fee Related
- 2003-09-05 BR BR0306309-7A patent/BR0306309A/pt not_active IP Right Cessation
- 2003-09-05 US US10/656,934 patent/US7081463B2/en not_active Expired - Lifetime
- 2003-09-05 MX MXPA05002622A patent/MXPA05002622A/es active IP Right Grant
- 2003-09-05 WO PCT/US2003/027956 patent/WO2004022558A2/en not_active Ceased
- 2003-09-05 JP JP2004534697A patent/JP4712384B2/ja not_active Expired - Fee Related
- 2003-09-05 EP EP03749479A patent/EP1601674B1/en not_active Expired - Lifetime
- 2003-09-05 RS YUP-2005/0208A patent/RS20050208A/sr unknown
- 2003-09-05 EA EA200500331A patent/EA009369B1/ru not_active IP Right Cessation
- 2003-09-08 AR ARP030103248A patent/AR041205A1/es unknown
- 2003-09-08 TW TW092124686A patent/TWI296627B/zh not_active IP Right Cessation
- 2003-09-09 CL CL200301814A patent/CL2003001814A1/es unknown
-
2005
- 2005-04-07 ZA ZA200502836A patent/ZA200502836B/en unknown
- 2005-04-08 NO NO20051743A patent/NO20051743L/no not_active Application Discontinuation
- 2005-10-04 US US11/242,654 patent/US7582649B2/en not_active Expired - Lifetime
-
2008
- 2008-12-03 US US12/327,437 patent/US8778956B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006500393A5 (https=) | ||
| CA2498275A1 (en) | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders | |
| RU2326881C9 (ru) | Конденсированные производные азолпиримидина, обладающие свойствами ингибитора фосфатидилинозитол-3-киназы (pi3k) | |
| KR101222330B1 (ko) | 아미노-헤테로시클릭 화합물 | |
| JP4754068B2 (ja) | δ−オピオイドレセプターに結合する４−［アリール（ピペリジン−４−イル）］アミノベンズアミド類 | |
| US20220282254A1 (en) | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd | |
| RU2435770C2 (ru) | ЗАМЕЩЕННЫЕ БИЦИКЛИЧЕСКИЕ ИМИДАЗО-3-ИЛАМИНЫ, ПРИГОДНЫЕ ДЛЯ РЕГУЛЯЦИИ mGluR5-РЕЦЕПТОРА | |
| JP2008522968A5 (https=) | ||
| JP2009518309A5 (https=) | ||
| JP2013515032A5 (https=) | ||
| JP2009522284A5 (https=) | ||
| JP2014518234A5 (https=) | ||
| JP2014524461A5 (https=) | ||
| JP2014523420A5 (https=) | ||
| TW201028422A (en) | Amino-heterocyclic compounds | |
| RU2350616C2 (ru) | Производные пиразоло- и имидазопиримидина | |
| JP2016523922A5 (https=) | ||
| JP2012525431A5 (https=) | ||
| JP2013519724A5 (https=) | ||
| RU2007119307A (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ПИРРОЛО[3, 2-d]ПИРИМИДИН-4-ОНА И ИХ ПРИМЕНЕНИЕ В ТЕРИПИИ | |
| JP2000159672A (ja) | 硝酸誘発耐性の処置剤 | |
| HRP20160359T1 (hr) | Derivati kinazolindiona, njihovo dobivanje i njihove terapijske primjene | |
| JP2013520407A5 (https=) | ||
| US10537560B2 (en) | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | |
| JP2006528229A5 (https=) |